Metabolic crosstalk between cancer and stromal cells: Implications for precision oncology.
Yang W., Ding Y., Tian H.
Narrative Review, published in Surg Oncol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Surg Oncol (2026)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41702306
- DOI
- 10.1016/j.suronc.2026.102366
Abstract (original English)
Metabolic reprogramming is a hallmark of cancer that extends beyond the boundaries of individual tumor cells to encompass a complex metabolic network within the tumor microenvironment (TME). Cancer cells engage in dynamic metabolic crosstalk with stromal components including fibroblasts, immune cells, endothelial cells, and adipocytes through the exchange of metabolites, signaling molecules, and extracellular vesicles. These interactions coordinate energy production, redox homeostasis, and biosynthetic pathways that sustain tumor growth, angiogenesis, immune evasion, and therapeutic resistance. Cancer-associated fibroblasts (CAFs) supply lactate, amino acids, and lipids that fuel tumor anabolism; immune cells undergo metabolic suppression under nutrient competition and acidic stress; endothelial and adipose cells contribute to angiogenesis and metastatic adaptation through glycolysis and lipid transfer. This metabolic dialogue is governed by key signaling pathways (HIF-1α, mTOR, AMPK, c-Myc, PPAR, NRF2) and modulated by epigenetic mechanisms linking metabolic flux to gene expression. Understanding these multilayered communications provides novel insights into the cooperative and competitive nature of tumor metabolism. Emerging technologies such as spatial metabolomics and single-cell multi-omics are now enabling the identification of patient-specific metabolic dependencies. Tar
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.